论文部分内容阅读
目的:研究肿瘤坏死因子相关凋亡诱导配体(TRAIL)启动子区-716A/G位点单核苷酸多态性(SNP)与影响前列腺癌危险因素的关系。方法:应用聚合酶链反应-连接酶特异检测技术(PCR-LDR)分析186例前列腺癌患者TRAIL基因-716位点的多态性,比较不同基因型与前列腺癌患者诊断时的前列腺癌特异性抗原(PSA)、Gleason评分和TNM临床分期的关系。结果:TRAIL-716G(AG+GG)等位基因与PSA、Gleason评分和TNM临床分期均具有显著的相关性(adjusted OR=0.04,0.07,0.08;95%CI:0.01～0.14,0.02～0.29,0.03～0.21)。结论:TRAIL-A716G(AG+GG)等位基因可能与前列腺癌预后有关,携带TRAIL-716G(AG+GG)等位基因的前列腺癌患者可能预后较好。
OBJECTIVE: To study the relationship between the single nucleotide polymorphism (SNP) at the -716A / G promoter region of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and the risk factors of prostate cancer. Methods: PCR-LDL was used to analyze the polymorphism of TRAIL gene-716 locus in 186 cases of prostate cancer and to compare the specificity of prostate cancer in diagnosis of different genotypes and prostatic cancer patients Antigen (PSA), Gleason score and TNM clinical stage. Results: The allele of TRAIL-716G (AG + GG) was significantly correlated with PSA, Gleason score and TNM clinical stage (adjusted OR = 0.04,0.07,0.08; 95% CI: 0.01-0.14,0.02-0.29, 0.03 ~ 0.21). CONCLUSIONS: The TRAIL-A716G (AG + GG) allele may be associated with the prognosis of prostate cancer. Prostate cancer patients carrying the TRAIL-716G (AG + GG) allele may have a better prognosis.